Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J07BK02
|
| gptkbp:brand |
gptkb:Shingrix
|
| gptkbp:CDCRecommendation |
recommended for immunocompromised adults 19 years and older
recommended for adults 50 years and older |
| gptkbp:contains |
AS01B adjuvant system
recombinant glycoprotein E antigen |
| gptkbp:contraindication |
severe allergic reaction to any component
|
| gptkbp:dosingSchedule |
two doses, 2 to 6 months apart
|
| gptkbp:fullName |
Recombinant Zoster Vaccine
|
| https://www.w3.org/2000/01/rdf-schema#label |
RZV
|
| gptkbp:indication |
prevention of herpes zoster
prevention of shingles |
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
fatigue headache injection site pain myalgia |
| gptkbp:storage |
2°C to 8°C
|
| gptkbp:targetAudience |
adults aged 50 years and older
immunocompromised adults aged 19 years and older |
| gptkbp:WHOModelListEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:Rize-Artvin_Airport
|
| gptkbp:bfsLayer |
7
|